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In Brief A substantial portion of the engineered HIV gp120 immunogen eOD-GT8-elicited antibodies target non-CD4 binding site (bs) epitopes, potentially limiting its efficacy. Duan et al. used N-linked glycans to mask epitopes outside the CD4bs of eOD-GT8, leading to enhanced elicitation of CD4bs antibodies, including VRC01-class precursors, and reduced off-target antibody responses in a human V H 1-2 mouse model.
INTRODUCTION
The elicitation of protective antibodies against HIV-1 remains a major scientific challenge. While passive administration of HIV-1-specific neutralizing antibodies in animal models can fully protect against infection (Gautam et al., 2016; Julg et al., 2017; Mascola et al., 2000; Nishimura et al., 2017; Saunders et al., 2015) , the induction of such antibodies via immunization has not yet been achieved (Burton and Hangartner, 2016; Pegu et al., 2017) . Multiple broadly neutralizing antibodies (bNAbs) targeting the CD4-binding site (CD4bs), including VRC01, NIH45-46, VRC-PG04, VRC13, 3BNC117, CH103, and N6, have been isolated from HIV-1-infected individuals and can potently neutralize diverse strains of HIV-1 (Huang et al., 2016; Liao et al., 2013; Scheid et al., 2011; Wu et al., 2010 Wu et al., , 2011 Wu et al., , 2015 Zhou et al., 2015) . Many of these CD4bs-directed human bNAbs share three common characteristics, as typified by the prototype antibody VRC01, and are termed VRC01-class antibodies (Jardine et al., 2016b; Kwong and Mascola, 2012; Scheid et al., 2011; West et al., 2012; Wu et al., 2010 Wu et al., , 2011 Zhou et al., 2013) : (1) a IGHV1-2 heavy chain, (2) an unusually short 5-amino acid light chain complementarity-determining region 3 (CDRL3) loop, and (3) high levels of somatic hypermutation (SHM).
In contrast to the broad and potent neutralization activity of mature VRC01-class antibodies, inferred VRC01-class unmutated common ancestors (UCAs) or germline revertants show little or no detectable interaction with gp120 monomers or native envelope (Env) trimers Hoot et al., 2013; McGuire et al., 2013; Scharf et al., 2013; Zhou et al., 2010) . However, engineered gp120 Env or their outer domains (OD) derived from specific HIV-1 strains have been reported to bind VRC01-class germline precursors as well as to activate B cells expressing the corresponding B cell receptors in vitro or in vivo (Jardine et al., , 2016a McGuire et al., 2013 McGuire et al., , 2016 . One such construct, eOD-GT8 60-mer, an engineered, circularly permutated OD genetically fused to a 60 subunit self-assembling nanoparticle, binds VRC01-class precursors with high affinity (Jardine et al., 2016a) and has been shown to elicit VRC01-class germline precursors with a 5-amino acid CDRL3 in various IGHV1-2 knock-in mouse models or in immunoglobulin (Ig)-humanized mice Sok et al., 2016; Tian et al., 2016; Abbott et al., 2018) . However, eOD-GT8 also possesses significant off-target immunogenicity, as demonstrated by a high titer of immune serum binding to the CD4bs-knockout (KO) eOD-GT8 variant and by a high percentage of antigen-specific B cells reacting to the CD4bs-KO protein Sok et al., 2016; Tian et al., 2016) . Such off-target responses may reduce the effectiveness of priming and could present a major challenge for subsequent boost strategies.
One way to mitigate off-target immune responses is to alter the immunogen surface through targeted point mutations and deletions (Dey et al., 2007 (Dey et al., , 2009 Onda et al., 2008; Wyatt et al., 1993) . However, introduction of N-linked glycans by means of the NxS/T sequon (Marshall, 1974) to cover irrelevant epitopes provides a versatile alternative with potentially more predictable outcomes. Prior studies (Ahmed et al., 2012; Forsell et al., 2013; Garrity et al., 1997; Ingale et al., 2014; Lin et al., 2014; Pantophlet et al., 2003 Pantophlet et al., , 2004 Sampath et al., 2013; Selvarajah et al., 2005 Selvarajah et al., , 2008 involving HIV-1 gp120 core, influenza hemagglutinin, or Plasmodium vivax Duffy protein have shown that off-target antibody responses can be decreased through the introduction of N-linked glycans. However, this approach has not yet been employed to focus or enhance the elicitation of a specific class of neutralizing antibodies, such as the VRC01-class bNAbs. To focus the immune responses to the CD4bs, we used structural information to introduce sequons for N-linked glycans at 13 different locations on the non-CD4bs surface of eOD-GT8. The antigenic integrity of these glycan-masked variants was verified with VRC01-class bNAbs, their germline revertants, and non-CD4bs-specific antibodies. Glycan mutants with high binding to CD4bs-specific antibodies, but reduced binding to non-CD4bs-specific antibodies, were selected and further tested in an IGHV1-2*02 knockin mouse model. In this model, the knockin germline human IGHV1-2*02 heavy chain gene segment recombines with mouse D H and J H gene segments to generate a diverse repertoire of CDRH3s and pairs with the full repertoire of mouse Ig light chains. Here, we demonstrated that glycan masking of the non-CD4bs surface of eOD-GT8 reduced off-target immune responses and facilitated the elicitation of VRC01-class precursor antibodies.
RESULTS

Design of eOD-GT8 Glycan-Masking Mutants
Despite ten predicted native N-linked glycans on the surface of eOD-GT8, a considerable area of protein surface outside the CD4bs is exposed. To reduce off-target immunogenicity of eOD-GT8, we masked non-CD4bs regions from the humoral immune system by introducing N-linked glycans onto the OD portion of the eOD-GT8 60-mer surface using the crystal structure of the eOD-GT8 monomer (Jardine et al., 2016a) as a model. Thirteen potential sites for the introduction of NxT sequons were identified by using the following criteria: (1) surface residues at least 5 Å from the CD4bs and (2) not adjacent to native glycans, (3) NxT mutations not expected to disrupt the structure of eOD-GT8, and (4) high probability of glycosylation as determined from the sequence surrounding the sequon ( Figure 1A ). NxT sequons were used exclusively as they are glycosylated more efficiently than NxS sequons (Kaplan et al., 1987; Kasturi et al., 1995) . Thirteen single glycan mutants, each containing one added glycan, were created for individual evaluation (eOD-GT8-mut1-12 and eOD-GT8-mut23; Figure 1B and Table S1 ). Structural modeling of the added glycans revealed the extensive non-CD4bs surface that could be covered by these glycan additions ( Figures 1C  and 1D) .
To maximize the masking area while ensuring protein stability, we further designed 35 multi-glycan mutants, each containing 2-6 of the 13 new glycans (eOD-GT8-mut13-22 and eOD-GT8-mut24-48 in Table S1 ). As previous studies have suggested that protruding loops tend to be immunogenic (Novotný et al., 1986; Thornton et al., 1986) , we focused on such regions of the non-CD4bs surface of eOD-GT8 as potential immunogenic hotspots when creating groupings for glycan masking. Examination of the eOD-GT8 monomer crystal structure indicated that the glycans from eOD-GT8-mut1, 2, 3, 7, 10, and 11 were each located on protruding loops. Additionally, in three mutants (eOD-GT8-mut24, 27, and 39), we moved the native glycan at 289 to position 287 to improve glycan coverage. Finally, the conserved N276 and N463 glycans existing in more than 90% of HIV-1 strains were also incorporated in eOD-GT8-mut42-48 (Table S1) .
eOD-GT8 60-mer Glycan-Masked Mutants 15, 16, 21, and 33 Have the Preferred Antigenic Profiles All 48 mutants were expressed in mammalian Expi293 cells using the same lumazine synthase nanoparticle format as the original eOD-GT8 60-mer, and antigenic assessment was carried out directly on the cell supernatants. Two separate panels of antibodies were used: (1) CD4bs-specific antibodies to evaluate the antigenic integrity of the CD4bs and (2) non-CD4bs-specific antibodies to evaluate the extent of glycan masking. The former panel included VRC01, its V gene germline revertant VRC01 gl, and the VRC-PG04 V gene germline revertant VRC-PG04 gl (Wu et al., 2011) , whereas the latter panel included a polyclonal rabbit anti-gp120 serum, two non-CD4bs monoclonal antibodies (mAbs) (Figure 2A , X1A2 and X1C6) isolated from eOD-GT6 60-mer-immunized XenoMouse (see STAR Methods), and two non-CD4bs mAbs ( Figure 2A , mA9 and mE4) isolated from eOD-GT8 60-mer-immunized IGHV1-2 knockin mice . The non-CD4bs-specific antibodies and serum generally recognized eOD-GT8 and eOD-GT8 KO proteins equally well (Figures 2A and S1 ).
All but 1 (eOD-GT8-mut4 60-mer) of the 13 single glycan mutants maintained strong binding to the CD4bs-specific antibodies, but none displayed decreased binding to all the non-CD4bs antibodies (Figure 2A ). Compared to single glycan mutants, four multi-glycan mutants (eOD8-GT8-mut15, 16, 21, and 33 60-mers) displayed preferable antigenic profiles (Figure 2A , marked by colored asterisks). Each showed strong recognition by CD4bs-specific mAbs and low binding to all or most non-CD4bs antibodies. Not surprisingly, these four mutants contained glycans that exhibited reduced recognition by non-CD4bs antibodies among the single glycan mutants (eOD8-GT8-mut1, 2, 4, 7, and 11 60-mer) as well as glycans located on potentially immunogenic protruding loops (from eOD8-GT8-mut1, 2, 3, 7, 10, and 11 60-mers) ( Figure 1D ).
We purified the four best glycan-masked mutants for further characterization using affinity and size exclusion chromatography ( Figure S2 ). These mutants were observed by ELISA to maintain high affinity to a panel of 11 VRC01-class germline revertant antibodies and 4 mature VRC01-class bNAbs, similar to the parental eOD-GT8 60-mer ( Figure 2B , left box). We also investigated the binding affinities of these glycan-masking mutants to a panel of 25 human VRC01-class antibody precursors (HuGL1-25) isolated from naive human B cells using an eOD-GT8 monomer as a probe (Jardine et al., 2016a) . By ELISA, the four glycan mutants were observed to maintain strong binding to the high-affinity precursors ( Figure 2B , marked with black arrowheads) and to have reduced binding to lower-affinity precursors relative to the parental eOD-GT8 60-mer. When binding of 19 of these HuGL antibodies was examined by surface plasmon resonance (SPR), the antigen binding fragments (Fabs) of these precursors were observed to have affinities to eOD-GT8 ranging from 0.07 to 16 mM, consistent with the K D values previously reported (Jardine et al., 2016a) . The glycan mutants all showed less than a 4-fold reduction of binding affinity to these precursors relative to eOD-GT8 60-mer ( Figures 2C and 2D ). eOD-GT8-mut16 60-mer showed the least reduction (1.3-fold), with a geometric mean binding affinity of 2.5 mM to these human VRC01-class precursors compared to 2.0 mM for eOD-GT8 60-mer. In summary, out of 48 mutants, eOD-GT8-mut15, 16, 21, and 33 60-mer showed the best antigenic profiles for masking non-CD4bs epitopes with minimal reduction in affinity to human VRC01-class bNAbs or their precursors.
Glycan-Masked eOD-GT8 Mutants 15, 16, 21, and 33 60-mers Contained Introduced Glycans and Formed Complete Particles We assessed the molecular assembly of the four best mutants (eOD-GT8-mut15, 16, 21, and 33-60mers) by negative stain EM. All four mutants formed spherical nanoparticles, similar to the parental eOD-GT8 60-mer, with a lumazine synthase inner core of 16-18 nm in diameter and an eOD outer layer of 4.2-5.8 nm in thickness ( Figure 3A) . We also examined the glycan occupancy at each predicted N-linked glycan sequon for the four eOD-GT8 60-mer mutants and the parental eOD-GT8 60-mer by liquid chromatography mass spectrometry (LC-MS). All ten predicted native N-linked glycosylation sites in the parental eOD-GT8 60-mer had greater than 80% glycan occupancy ( Figure 3B , green bars). For eOD-GT8-mut15, 16, 21, and 33 60-mer, all added glycosylation sites had occupancies greater than 85% except the added N380 glycan (from single glycan mutant eOD-GT8-mut7) in eOD-GT8-mut16 and 21 60-mer, which showed occupancies of 59% and 73%, respectively ( Figure 3B , orange bars). In conclusion, eOD-GT8-mut15, 16, 21, and 33 60-mer, each of which shared preferred antigenic binding profiles, also formed well-assembled particles and were glycosylated at expected locations.
Glycan Masking of eOD-GT8 60-mers Focused the Antibody Response to the CD4bs in Human IGHV1-2*02 Knockin Mice To investigate the impact of glycan masking on focusing the antibody response to the CD4bs and the elicitation of VRC01-class precursors, we used a previously described homozygous IGHV1-2*02 knock-in mouse model . In this model, approximately 45% of naive B cells express a human IGHV1-2*02 gene segment which in a given B cell is recombined with one of the 13 mouse D segments and one of the 4 mouse J H Figure 2 . eOD-GT8 60-mer Glycan-Masked Mutants 15, 16, 21, and 33 Have High Affinity to CD4bs Antibodies and Low Affinity to Non-CD4bs Antibodies (A) Heatmaps illustrating the ELISA binding (OD450 values in blue shading) of 48 different eOD-GT8 60-mer mutants to CD4bs-specific mAbs (green box) and non-CD4bs antibodies or serum (red box). Four mutants, marked by asterisks, bound with lowest affinity to non-CD4bs antibodies while they retained high affinity for CD4bs-specific mAbs. X indicates assay not performed. (B) Heatmap displaying the ELISA binding (area under the curve [AUC], in blue shading) of eOD-GT8 (eOD8), eOD-GT8 KO (KO), and glycan mutants eOD-GT8-mut15, 16, 21, and 33 60-mer to a panel of CD4bs-specific VRC01-class antibodies and germline revertant antibodies, and 25 human VRC01-class IgG precursors (HuGL1-25). Highaffinity binders (K D to eOD-GT8 < 3 mM) are marked with arrowheads. Rabbit-anti-gp120 serum and two non-CD4bs mAbs were used as controls. The asterisks in (A) and the affinity data in (C) and (D) are color coded as follows: eOD-GT8-mut15, blue; eOD-GT8-mut16, red; eOD-GT8-mut21, magenta; and eOD-GT8-mut33, green. See also Figure S1 . segments to form diverse CDRH3s, and these heavy chains then pair with any one of the full repertoire of mouse light chains . To confirm the consistency and stability of the genotype of these transgenic mice, we bred and genotyped the mice and confirmed the persistence of the knockin IGHV1-2*02 gene segment ( Figure S3A ). Based on fluorescence-activated cell sorting (FACS) analysis of several cell surface markers, splenic T and B cells, IgM + and IgG + B cell populations of IGHV1-2*02 knockin mice appeared comparable to C57BL/6 and wild-type littermates ( Figures S3B and S3C ). The immunogenicity of our most promising glycan-masked immunogens (eOD-GT8-mut15, 16, 21, and 33 60-mer) was compared to the eOD-GT8 60-mer control by immunizing these mice once using poly(I:C) as an adjuvant ( Figure 4A ). Two to three weeks after immunization, mice were sacrificed, serum and spleen collected, and the CD4bs-specific immune response in the serum or in the IgG + B cell compartment was analyzed using the eOD-GT8 monomer and its CD4bs-KO mutant, eOD-GT8 KO, as protein probes. As shown previously , the sera from eOD-GT8 60-mer-immunized mice displayed similar reactivity to eOD-GT8 and eOD-GT8 KO, suggesting that much of the elicited serum response targeted nonCD4bs epitopes on eOD-GT8. By comparison, sera from mice immunized with the eOD-GT8 60-mer glycan-masked mutants showed greater reactivity to eOD-GT8 relative to the CD4bs KO mutant ( Figure 4B ). Quantification of this difference revealed that the percentage of the CD4bs-specific response increased from 42% in the eOD-GT8 60-mer-immunized mice to 93%, 87%, 94%, and 74% in the eOD-GT8-mut15, 16, 21, and 33 60-mer-immunized mice, respectively ( Figure 4C ). Furthermore, the absolute CD4bs-specific serum response, as judged by the serum dilution (ED 50 ) difference in binding to eOD-GT8 versus eOD-GT8 KO, from the eOD-GT8-mut15, 16, and 33 60-mer-immunized mice was higher than that from the eOD-GT8 60-mer-immunized mice (2,956, 7,928, 4,611, versus 2,525, respectively) ; only eOD-GT8-mut21 60-mer-immunized mice showed a decreased CD4bs-specific ED 50 value ( Figure 4C ). These results indicated that the added glycans in eOD-GT8-mut15, 16, and 33 60-mer resulted in a substantially reduced serum response to non-CD4bs epitopes while maintaining accessibility to the CD4bs. We also determined the frequency of CD4bs-specific B cells among eOD-GT8-specific IgG + B cells (B220 + IgG + ) by using fluorophore-labeled eOD-GT8 and eOD-GT8 KO monomers as probes Sok et al., 2016; Tian et al., 2016) . CD4bs-specific B cells were defined as those that bound to eOD-GT8 but not to the CD4bs-KO version of eOD-GT8, whereas the non-CD4bs-specific B cells corresponded to those that bound to both eOD-GT8 and eOD-GT8 KO ( Figure 4D ). The frequency of the CD4bs-specific B cells in the total IgG + B cell Figure S2 ).
population was increased from a mean of 1.1% in the eOD-GT8 60-mer-immunized group to 4.2%, 2.7%, and 3.3% in the eOD-GT8-mut15, 16, and 33 60-merimmunized groups, respectively. Likewise, average non-CD4bs-specific B cell frequency in the total IgG + B cell population was reduced from 2.5% in the eOD-GT8 60-mer-immunized group to 0.7%, 1.2%, and 1.0% in the eOD-GT8-mut15, 16, and 33 60-mer-immunized groups ( Figure 4E ). eOD-GT8-mut21 60-mer was an exception in that it elicited a reduced frequency of both CD4bs-specific and non-CD4bs IgG + B cells. The frequency of the CD4bs-specific IgG + B cells among all elicited eOD-GT8 + IgG + B cells increased from a mean of 37% in the eOD-GT8 60-mer-immunized control group to 87%, 73%, 77%, and 83% in eOD-GT8-mut15, 16, 21, and 33 60-mer-immunized groups, respectively ( Figure 4F ). To address the possibility that the mice may have mounted an immune response against neo-epitopes generated by glycan masking that parental eOD-GT8-based probes would not detect, we also examined serum and B cell responses from the respective immunization groups using immunogen-matched eOD-GT8-mut15, 16, and 33 probes. Since ELISA and flow cytometry assays indicated similar CD4bs-specific serum and B cell responses between the probe sets ( Figure S4 ), we continued to use eOD-GT8 and eOD-GT8 KO probes for the rest of the study. To evaluate the effect of different immunogen doses and types of adjuvants as well as an additional boost on the elicitation of VRC01-class antibodies, we performed two further experiments using the same mouse model (Figures 5 and S3E ). Similar increases in frequency of both the CD4bs-specific serum response and the CD4bs-specific IgG + B cell response were consistently observed for eOD-GT8-mut15, 16, and 21 60-mer, relative to eOD-GT8 60-mer, when immunizations were performed with different dosages or different adjuvants ( Figures 5A-5C ). Evaluation of two additional mutants, eOD-GT8-mut17 and 18, in an independent immunization study at a 30 mg dose also revealed comparable results ( Figures 5B and 5C ). Finally, when we analyzed the results from all immunization experiments together, we observed statistically higher CD4bs-specific serum responses for immunogens eOD-GT8-mut15 60-mer and eOD-GT8-mut16 60-mer relative to eOD-GT8 60-mer ( Figure 6A ) and statistically higher frequencies of CD4bs-specific B cells were observed for all six evaluated immunogens relative to eOD-GT8 60-mer ( Figure 6B ). In summary, glycan masking of the eOD-GT8 60-mer immunogen was shown to increase the elicitation of CD4bs-specific serum antibodies in both overall titers ( Figure 4C ) and as a percentage of antigen-specific response ( Figures 4C, 5B, and 6A) . Moreover, glycan masking of eOD-GT8 increased the CD4bs-specific IgG + B cell frequency among both eOD-GT8-specific IgG + B cells ( Figures 4F, 5C , and 6B) and total IgG + B cells ( Figure 4E ).
Glycan Masking of eOD-GT8 60-mers Enhanced the Elicitation of VRC01-Class Antibodies in Human IGHV1-2*02 Knockin Mice To determine whether glycan-masked eOD-GT8 60-mer immunogens elicited VRC01-class precursors in IGHV1-2*02 knockin S3 and S4  and Tables S2, S5, and S6. mice, we performed single-cell RT-PCR on splenic antigen-sorted CD4bs-specific IgG + B cells from these immunized mice as described previously . In most cases, we first amplified and sequenced the Igk light chains of the IgG antibodies expressed by the sorted B cells to search for a 5-amino acid CDRL3, a signature of VRC01-class antibodies. From B cells that exhibited this Igk light chain signature, we then amplified and sequenced their corresponding heavy chains to confirm that the light chains were paired with human IGHV1-2 heavy chains. Consistently, all 5-amino acid CDRL3 Igk light chains, for which we could amplify a paired heavy chain, were found to pair with the human IGHV1-2. Thus, we could use the number of CD4bs-specific B cells expressing a 5-amino acid CDRL3 Igk light chain as a measure of the number of VRC01-class precursor antibodies . We subsequently calculated the frequency of VRC01-class precursors (containing a human IGHV1-2 heavy chain and a mouse light chain with 5-amino acid CDRL3) across all three immunization studies relative to the total number of sequenced Igk light chains within each respective immunogen group. This frequency was calculated per mouse ( Figure 6C and Tables S2-S4), as a mean value for immunized animals ( Figure 6C ) and as an overall frequency per immunogen ( Figure 6D) . By this analysis, we observed an average of 3.2% of the amplified Igk light chains from CD4bs-specific B cells elicited by eOD-GT8 60-mer immunization had the VRC01-class antibody signature. In contrast, the mean value of VRC01-class precursors from mice immunized with eOD-GT8-mut15, 16, or 33 60-mer was 7.0%, 9.1%, and 3.7%, respectively ( Figure 6C) . Notably, eOD-GT8-mut16 60-mer elicited a statistically significant (Mann-Whitney test, p = 0.007) 2.8-fold increase in the mean frequency of VRC01-class antibodies relative to eOD-GT8 60-mer (9.1% versus 3.2%) ( Figure 6C , ANOVA Kruskal-Wallis test, p = 0.0159) and a 4.2-fold increase in the overall frequency of VRC01-class antibodies among the cloned CD4bs-specific antibodies (9.7% versus 2.3%) ( Figure 6D ).
The CDRL3s of the isolated VRC01-class antibody precursors elicited by eOD-GT8-mut15, 16, 17, and 21 60-mers were found to be enriched for the QQY motif found in the VRC01 antibody. CDRL3 sequences elicited by the eOD-GT8-mut16 60-mer showed some enrichment for Q at position 96 (observed in 11 out of 28 sequences), but the other immunogens did not enrich for the E/Q residue found in mature VRC01-class antibodies (Figure 6E) . Based on the observed Igk V-and J-gene usage and CDRL3 sequences, five VRC01-class antibody light chain lineages were shared between antibodies elicited by parental eOD-GT8 60-mer and glycan-masked eOD-GT8 60-mer mutants, suggesting that the same sets of light chain unmutated common ancestors (UCAs) were stimulated by these immunogens (Table S5 , boxed in black). The CDRH3s of the cloned VRC01-class precursors varied in sequence and length, ranging from 7 to 15 amino acids, consistent with the diverse CDRH3s associated with IGHV1-2*02 in this mouse model and in human PBMCs (Jardine et al., 2016a; Tian et al., 2016) . Since these mice were immunized only once or twice, heavy chains of the isolated VRC01-class precursors accumulated minimal SHM (<6.5%) ( Figure S5 and Table S6 ). In summary, these data showed that glycan masking of eOD-GT8 enhanced the elicitation of VRC01-class precursors in the immunized IGHV1-2*02 knockin mice.
DISCUSSION
The eOD-GT8 60-mer has been shown to elicit VRC01-class precursors in IGHV1-2*02 knockin mouse models (Dosenovic et al., 2015; Jardine et al., 2015) . In the mouse model used here, IGHV1-2*02 recombines with the normal complement of mouse D H and J H gene segments, thereby allowing the generation of (B and C) Scatterplots (mean ± SEM) showing the percent CD4bs-specific sera responses (B) and percent CD4bs-specific B cells (relative to the total antigen-specific populations) (C) elicited by the indicated immunizations. Data points from the second and third immunization studies are depicted by squares and triangles, respectively. See also Figure S3 and Tables S3-S6.
B cells that express a diverse array of CDRH3s in the IGHV1-2*02 heavy chain. Another feature of this mouse model is that IGHV1-2*02 is located at the most proximal end of the mouse V H cluster relative to D segments. The proximity, along with the deletion of the IGCR1 regulatory element in the V H -D intervening region, strongly favors the utilization of IGHV1-2*02 during V(D)J recombination . For this reason, IGHV 1-2*02 heavy chains account for 45% of total heavy chains , a frequency which is 15.5 times higher than that in naive B cells of human PBMCs (2.9% ± 1.3%) . Five-amino acid CDRL3 Igk chains were detected at a frequency of 0.15% , which is 6.3 times lower than the frequency in human PBMCs (0.95% ± 0.57%) . Overall, we estimated that the potential VRC01-class precursors were expressed in this mouse model at a frequency of 0.068% (45% 3 0.15%), which is approximately 2.4-fold higher than in humans (2.9% 3 0.95%). The higher frequency of potential VRC01-class precursors helped to compensate for the small size of the B cell compartment in mice. Thus, in terms of absolute number and diversity of B cells expressing potential VRC01 precursors, the IGHV1-2*02-rearranging mouse model may offer a closer approximation to the human repertoire than conventional knockin mice. eOD-GT6 , a VRC01-class immunogen with lower affinity to VRC01-class precursors than eOD-GT8, which failed to isolate VRC01-class naive B cells from human PBMCs (Jardine et al., 2016a) , also failed to elicit VRC01-class precursors at detectable level in this mouse model, highlighting the stringency of the model. In a prior study, we were able to elicit VRC01-class antibodies with a single immunization of eOD-GT8 60-mer, though many of the elicited antibodies and IgG + B cells targeted non-CD4bs epitopes . To more effectively focus the antibody immune response to the CD4bs, we used sequence and structural information to selectively add N-linked glycans to mask the non-CD4bs regions of eOD-GT8. In three independent experiments with different adjuvants and immunization schema in the IGHV1-2-rearranging mouse model, glycan masking mutants were shown to enhance the specificity of CD4bs responses in both sera and the IgG + B cell pools with the best results observed for the eOD-GT8-mut16 60-mer. Moreover, VRC01-class precursor B cell receptors (BCRs) were isolated at higher frequencies from mice immunized with glycan masking mutants than those immunized with eOD-GT8 60-mer, with the highest frequency in eOD-GT8-mut16 60-mer-immunized mice. By blocking non-CD4bs epitopes, which are often dominant and more immunogenic than the CD4bs epitope, we likely reduced the competition that the VRC01-class B cell precursors would face during their activation and maturation, and provided a greater opportunity to access limited resources such as antigen-presenting cells and T cell help and to mature into IgGsecreting B cells. As noted earlier, this mouse model overrepresented the number of VRC01-class precursor B cells, compared to the naive human repertoire. Thus, it is difficult to predict how much improvement might be attained with a glycan variant compared to the wild-type eOD-GT8 in humans.
A phase I study of the eOD-GT8 60-mer is planned to begin later this year. If this immunogen is shown to elicit VRC01-class (E) Sequence conservation of 5-amino acid CDRL3 loops of elicited VRC01-class antibodies. X refers to any amino acid and F refers to hydrophobic residues. Sequence Logo plots illustrate the amino acids distributions at each CDRL3 position in VRC01-class antibodies elicited by the indicated immunogens. The relative height of each letter denotes the frequency for observing that amino acid at that position. eOD-GT8-mut33 60-mer was not shown due to low numbers of isolated sequences (3 in total). See also Figures S3, S5 , and S6 and Tables S2-S6. antibodies in humans, it is reasonable to expect that improved variants, such as those described here, could further focus the immune response on the CD4bs. Of note, glycans not crowded by other glycans can have a degree of conformational flexibility that enlarges their footprint on the protein surface (Stewart-Jones et al., 2016) . Thus, the added glycans, especially those nearest the CD4bs, such as glycans at residue 380 and 482, may have restricted the approach angles from which a CD4bs-specific BCR could access the CD4bs. Accordingly, only those BCRs with an optimal approach angle would have had the potential to develop into VRC01-class bnAbs. Among the 25 potential VRC01-class precursors isolated from naive human B cells, the top nine antibodies with the highest eOD-GT8 binding affinities (K D < 3 mM) recognized all of the glycan mutants with affinities comparable to their interaction with eOD-GT8 60-mer. However, the loweraffinity human precursor antibodies bound the glycan mutants much more weakly than to eOD-GT8 60-mer. These lower affinities may have been due to approach angles not optimally compatible with added glycans, though eOD-GT8 interactions with germline-encoded VH1-2 should significantly constrain the angle of approach. The glycan mutants may have therefore preferentially selected for high-affinity precursors, which likely included those with optimal approach angles, but may have also reduced capacity to prime lower-affinity precursors. A recent study has shown that antibody precursor affinity toward its cognate immunogen can have a large effect on B cell recruitment, differentiation, and antibody maturation (Abbott et al., 2018) . Thus, the ability of glycan mutants to further focus the antibody response while maintaining high affinity to target antibody precursors is a potential improvement in germline targeting vaccine design.
The initial ELISA analysis of 13 individual mutants indicated that eOD-GT8-mut1, 2, 4, 5, 7, 11, and 23 60-mer were among the best at masking the binding of non-CD4bs antibodies. Five of these glycans (from eOD-GT8-mut1, 2, 4, 5, and 23) are all clustered together in the same region (cluster 1) on a face opposite the CD4bs (Figure S6B ), suggesting that this may be an immunogenic hotspot. The other two glycans, from eOD-GT8-mut7 and 11, are both located on nearby protruding loops which may represent another immunogenic hotspot (cluster 2). Only two of these seven glycans, from eOD-GT8-mut1 and 2, would be accessible in the context of the envelope trimer. The rest of the glycans mask new surfaces created in the context of an isolated eOD and thus served to block undesired neoepitopes in this immunogen. Of the four best glycan combination mutants examined (eOD-GT8-mut15, 16, 21, and 33), each had at least two glycans from the first cluster and one or more glycans from the second cluster, suggesting that both glycan clusters may have been important for suppressing elicitation of nonCD4bs antibodies. Notably, eOD-GT8-mut15 60-mer, which had only three added glycans, performed very well in immune focusing relative to the other three mutants with 4-6 added glycans. This suggested that the three glycans in eOD-GT8-mut15 sufficed to cover the most dominant off-target surfaces. However, eOD-GT8-mut16 60-mer with five added glycans was ultimately the most specific for the elicitation of CD4bs-specific serum and of VRC01-class precursors, which may have been due, in part, to the fact that this mutant retained affinities nearly as high as eOD-GT8 for human naive VRC01-class precursors. Although shown to be an effective prime, the glycan-masked versions of eOD-GT8 60-mer would likely require further vaccine boosts with immunogens designed to direct affinity maturation of the initial antibody recombinants to resemble mature VRC01-class bNAbs. This will likely entail design of intermediate immunogens that more closely resemble prevalent strains at the CD4bs epitope Steichen et al., 2016; Escolano et al., 2016; Tian et al., 2016) .
In summary, we used structure-guided glycan masking, followed by antigenic characterization, to identify variants of the eOD-GT8 60-mer immunogen capable of focusing the immune response on the CD4bs and, specifically, to improve the ability of this germline-targeting priming immunogen to elicit VRC01-class responses, an important class of HIV-1-neutralizing antibodies. The enhanced antibody response elicited by these glycan-masked immunogens may facilitate the ability of subsequent boost immunizations to maturate these antibody precursors into HIV-1-neutralizing antibodies. The best of these glycan mutants, eOD-GT8-mut16 60-mer, may serve as a second generation of eOD-GT8 60-mer for further evaluation in clinical trials. Our results suggested that glycan masking could be applied to focus immune responses to key epitopes on other HIV-1 immunogens or vaccine candidates for other pathogens.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, John R. Mascola (jmascola@nih.gov) .
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation and characterization of IGHV1-2 single knock-in mouse models The generation and characterization of the IGHV1-2*02 mouse model used in this study have been described in detail in a previous publication . Briefly, human IGHV1-2*02 segment substitutes for the mouse V H 81X segment at the IgH locus, and IGCRI was deleted from the same IgH allele. In this setting, IGHV1-2*02 segment is preferentially utilized for V(D)J recombination and accounts for about 45% of heavy chains in the antibody repertoire. These genetic modifications were introduced into EF1 ES cell line, which was derived from an F1 hybrid mouse (129/Sv and C57BL/6). IGHV1-2*02 replacement and IGCRI deletion occurred on the IgH allele from the 129/Sv strain. Correctly modified ES clones were injected into Rag2 deficient blastocysts to generate chimeric mice (Chen et al., 1993) . The chimeric mice were bred with the 129/Sv strain mice for germline transmission. Heterozygous IGHV1-2*02 knock-in mice were interbred to produce homozygous knock-in mice, which are used for the experiments in this study. Ten to 14-week-old female/male homozygous IGHV1-2*02 mice were used for all the experiments. Littermates were randomly assigned to experimental groups for each independent study. All the mice were housed in the animal facility of the Vaccine Research Center (VRC), NIAID, NIH, Bethesda, MD. All animal experiments were reviewed and approved by the Animal Care and Use Committee of the Vaccine Research Center, NIAID, NIH, and all animals were housed and cared for in accordance with local, state, federal, and institute policies in an American Association for Accreditation of Laboratory Animal Care (AAALAC)-accredited facility at the NIH. For B cell characterization, splenic B cells were stained with anti-B220, anti-IgM, anti-IgD, anti-IgG antibodies and analyzed with flowcytometry.
Human: Expi293F TM cells Expi293F TM cells were purchased from ThermoFisher Scientific Inc. (Invitrogen, cat# A14528; RRID: CVCL_D615) for protein production. It is derived from the HEK293-F cell line, originating from a female fetus.
METHOD DETAILS
Design of eOD-GT8 glycan-masking mutants Using the crystal structure of eOD-GT8 monomer (Jardine et al., 2016a) , we identified all surface residues with exposed Cb atoms (or Ca in the case of glycine) equal to or greater than 5 Å from the CD4bs and from potential native glycans and these were designated as non-CD4bs residues. Each non-CD4bs position was examined using PyMol (The PyMol Molecular Graphics System, version 1.8.6; Schrö dinger, LLC) for the potential structural effects of incorporating an NxT sequon (where X is not a proline). NxT sequons were used instead of NxS since they are known to glycosylate more efficiently than NxS sequons (Kaplan et al., 1987; Kasturi et al., 1995) . Positions where the introduction of asparagine or the downstream i+2 threonine could potentially decrease protein stability (e.g., by steric clash, loss of hydrogen bond, interruption of hydrophobic core packing, etc.) were discarded. The remaining positions were further evaluated for sequence-based glycosylation potential using the NetNGlyc server (http://www.cbs.dtu.dk/services/ NetNGlyc/). Glycosylation sites with scores less than 0.5 were discarded. Each potential glycan was also modeled onto the eOD-GT8 structure using the program Glycosylate (He and Zhu, 2015) to aid in the visual inspection of potential glycan locations as well as the selection of various glycans to combine together in individual designs. The identification of new glycan sites located on protruding loops was performed by examining the monomer eOD-GT8 crystal structure using Pymol. For one sequon (at Hxbc2 residue 268), the preceding glutamate was mutated to glycine to further reduce the immunogenicity of this site (Hopp and Woods, 1981) . For another sequon (at Hxbc2 residue 419) a glycine was introduced just after the sequon to counter the low glycosylation potential caused by the adjoining proline (Mellquist et al., 1998) . For five of the mutants 23, 40, 41 and 45) , an additional set of two residues were also mutated to reduce immunogenicity (E267G and E268G) or to improve overall stability (I477L and D478N). See Table S1 . All structural figures were created using the eOD-GT8 crystal structure (PDB 5IES) as a template and the molecular graphics program PyMol (The PyMol Molecular Graphics System, version 1.8.6; Schrö dinger, LLC). (Crooks et al., 2004) . CDRL3 sequences of eOD-GT8 60-mer-elicited antibodies are from 7 antibodies in this study and 17 antibodies from previous published study in the same VH1-2*02 KI mice immunized with eOD-GT8 60-mer at 30 or 60 mg once with Poly I:C adjuvant .
Surface plasmon resonance (SPR)
Affinities of antibody-antigen interactions were measured as previously described Tian et al., 2016) . Briefly, we measured kinetics and affinities of antibody-antigen interactions on a ProteOn XPR36 (Bio-Rad) using GLC Sensor Chip (Bio-Rad) and 1x HBS-EP+ pH 7.4 running buffer (20x stock from Teknova, Cat. No H8022) supplemented with BSA at 1mg/ml. We followed the Human Antibody Capture Kit instructions (Cat. No BR-1008-39 from GE) to prepare chip surfaces for ligand capture. In a typical experiment, about 6000 RU of capture antibody was amine-coupled in all 6 flow cells of the GLC Chip. Regeneration was accomplished using 3M Magnesium Chloride with 180 s contact time and injected four times per each cycle. Raw sensorgrams were analyzed using ProteOn Manager software (Bio-Rad), including interspot and column double referencing, and either Equilibrium fits or Kinetic fits with Langmuir model, or both, were employed when applicable. Analyte concentrations were measured on a NanoDrop 2000c Spectrophotometer using Absorption signal at 280 nm.
Mass Spectrometry Glycan Analysis
An aliquot of each sample was denatured by incubating with 10 mM of dithiothreitol at 56 C for an hour and alkylated by 55 mM of iodoacetamide for 45 minutes in dark prior to digestion with proteases optimized based on amino acid sequence of each target protein. Specifically, each aliquot was treated with Arg-C (Promega) and Glu-C (Promega) sequentially. Following digestion, the samples were deglycosylated by Endo-H (Promega) followed by PNGaseF (GlykoÒ, Prozyme) treatment in the presence of O18-water. The resulting peptides were separated on an Acclaim PepMap RSLC C18 column (75 mm x 15 cm) and eluted into the nano-electrospray ion source of an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific) with a 180-min linear gradient consisting of 0.5%-100% solvent B over 150 min at a flow rate of 200 nL/min. The spray voltage was set to 2.2 kV and the temperature of the heated capillary was set to 280 C. Full MS scans were acquired from m/z 300 to 2000 at 60k resolution, and MS2 scans following collision-induced fragmentation were collected in the ion trap for the most intense ions in the Top-Speed mode within a 5 s cycle using Fusion instrument software (v2.0, Thermo Fisher Scientific). The resulting spectra were analyzed using SEQUEST (Proteome Discoverer 1.4, Thermo Fisher Scientific) with full MS peptide tolerance of 20 ppm and MS2 peptide fragment tolerance of 0.5 Da, and filtered using ProteoIQ (v2.7, Premier Biosoft) at the protein level to generate a 1% false discovery rate for protein assignments. Site occupancy was calculated using spectral counts assigned to the O18-Asp-containing (PNGaseF-cleaved) and/or HexNAc-modified (EndoH-cleaved) peptides and their unmodified counterparts.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical comparisons using GraphPad Prism 7.01 Software (GraphPad Prism Software, Inc.) were performed only on the combined datasets with n > 3. For these comparisons overall nonparametric ANOVA Kruskal-Wallis tests were performed and if the p-values were less than 0.05 they were followed by nonparametric Mann-Whitney tests between two individual groups.
DATA AND SOFTWARE AVAILABILITY
The sequences of 73 elicited VRC01-class antibodies reported in this paper have been deposited at GenBank: MH485280 -MH485352 for the heavy chains and MH485207 -MH485279 for the light chains.
